Cardiol Therapeutics Files Preliminary Prospectus Supplement For Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed
Cardiol Therapeutics Files Preliminary Prospectus Supplement For Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.
Cardiol Therapeutics Inc. (纳斯达克:CRDL) (tsx:CRDL) ("Cardiol"或"公司"), 一家临床阶段的生命科学公司,专注于心脏病治疗的抗炎和抗纤维化治疗的研究和临床开发,很高兴宣布公司已就拟议中的公开发行(Class A普通股"Common Shares")提交了一份初步招股书补充("Supplement"), 以补充其短表基础招股说明书,日期为2024年7月12日("基础招股说明书")。该补充文件还在美国证券交易委员会(SEC)提交,作为一项Form-10修正的注册声明的一部分,该注册声明已于2024年7月16日获得SEC批准,符合加拿大与美国之间建立的多司法披露系统。
The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis, and for general and administrative expenses, working capital and other expenses.
公司打算利用本次发行的净收益支持用于治疗复发性心包炎的CardiolRx的临床开发,以及用于一般和管理性费用、营运资金和其他支出。
Canaccord Genuity is acting as the sole bookrunner in connection with the Offering.
Canaccord Genuity将担任发行的唯一包销商。
